Furthermore, it has a positive correlation with pro-inflammatory cytokines such as IL-6 and tumor necrosis factor-α (TNF-α), suggesting that Gal-9 inhibition could be a potential therapeutic approach in COVID-19 patients (123). The gene discussed is TNF; the disease is COVID-19.